Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives Average Rating of “Hold” from Analysts

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) has been assigned an average recommendation of “Hold” from the six research firms that are currently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and one has assigned a strong buy rating to the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $5.00.

Several research analysts have recently commented on the company. Wall Street Zen upgraded Zentalis Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Sunday, November 16th. Morgan Stanley reduced their target price on shares of Zentalis Pharmaceuticals from $8.00 to $4.00 and set an “equal weight” rating on the stock in a research note on Wednesday, November 12th. Leerink Partners reissued a “market perform” rating and issued a $2.00 price target on shares of Zentalis Pharmaceuticals in a research note on Tuesday, November 11th. Finally, Wedbush restated a “neutral” rating and set a $4.00 price target on shares of Zentalis Pharmaceuticals in a report on Tuesday, November 11th.

Insiders Place Their Bets

In other Zentalis Pharmaceuticals news, major shareholder Group Walters purchased 6,459,973 shares of the stock in a transaction dated Wednesday, December 31st. The stock was acquired at an average cost of $1.20 per share, for a total transaction of $7,751,967.60. Following the acquisition, the insider owned 13,509,973 shares in the company, valued at $16,211,967.60. This trade represents a 91.63% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Matrix Capital Management Comp sold 7,500,000 shares of the firm’s stock in a transaction dated Monday, December 15th. The stock was sold at an average price of $1.33, for a total value of $9,975,000.00. Following the sale, the insider directly owned 6,459,973 shares of the company’s stock, valued at $8,591,764.09. The trade was a 53.73% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 7,546,617 shares of company stock valued at $10,088,417 over the last quarter. 1.90% of the stock is owned by insiders.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. 5AM Venture Management LLC increased its position in shares of Zentalis Pharmaceuticals by 705.7% during the fourth quarter. 5AM Venture Management LLC now owns 3,947,913 shares of the company’s stock valued at $5,330,000 after acquiring an additional 3,457,913 shares during the last quarter. Millennium Management LLC boosted its position in shares of Zentalis Pharmaceuticals by 220.6% during the 1st quarter. Millennium Management LLC now owns 3,069,514 shares of the company’s stock worth $4,881,000 after purchasing an additional 2,111,951 shares during the period. Ishara Investments LP acquired a new stake in Zentalis Pharmaceuticals in the 4th quarter valued at approximately $1,782,000. Opaleye Management Inc. increased its holdings in Zentalis Pharmaceuticals by 342.6% in the 4th quarter. Opaleye Management Inc. now owns 1,400,906 shares of the company’s stock valued at $1,891,000 after purchasing an additional 1,084,356 shares during the last quarter. Finally, Balyasny Asset Management L.P. purchased a new stake in Zentalis Pharmaceuticals in the second quarter valued at approximately $1,126,000.

Zentalis Pharmaceuticals Stock Performance

Shares of Zentalis Pharmaceuticals stock opened at $2.42 on Friday. The business’s 50 day moving average price is $2.28 and its 200 day moving average price is $1.79. The company has a market cap of $174.85 million, a price-to-earnings ratio of -1.17 and a beta of 1.73. Zentalis Pharmaceuticals has a one year low of $1.01 and a one year high of $3.95.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for oncology. Leveraging a proprietary structure-based drug discovery platform, the company designs selective inhibitors aimed at critical cancer targets. Zentalis’ research and development efforts center on delivering differentiated therapies that address unmet medical needs in solid tumors and hematologic malignancies.

The company’s lead product candidate, ZN-c3, is an orally administered inhibitor of the p53-MDM2 interaction, currently being evaluated in Phase I clinical trials for advanced solid tumors and hematologic cancers.